About the Hepatocellular Carcinoma (HCC) Interest Group

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide; its incidence is increasing in the United States. Depending on disease extent and underlying liver status, patients may be treated with local, locoregional, and/or systemic therapy. The HCC IG was established to catalyze progress on the use of radiotherapy (RT) in the management of HCC.

Goals

1. To suggest how RT should be implemented in the management of HCC and identify future directions for the study of RT in HCC.

2. To share experiences using RT for HCC, including the use of radiosensitizers and stereotactic RT.

3. To discuss methods for performing preclinical studies of RT for HCC and biomarkers of response.

HCC IG Chairpersons

Chandan Guha, MBBS, PhD (Albert Einstein, CGUHA@montefiore.org)
Rafi Kabarriti, MD (Albert Einstein, rkarri@montefiore.org)
Teleconference Schedule

☐ The HCC meets virtually via the WebEx platform on the last Monday of each month at 8am ET, and at the NRG Oncology meeting biannually.

☐ The group membership is approximately 50.

Activities and Accomplishments

☐ Clinical Trials


☐ Publications


☐ Workshop

Interested in becoming a member of the HCC Interest Group?

☐ Please Contact the Interest Group Coordinator:

Masoor M. Ahmed, Ph.D.
Radiation Research Program
Division of Cancer Treatment & Diagnosis
National Cancer Institute
Tel: 240-276-5700
Email: mansoor.ahmed@nih.gov